Best Agriculture Stocks to Buy in 2020 Bayer Aktiengesellschaft (ETR:BAYN) reported first-quarter 2026 results that management said were in line with expectations, as growth in Crop Science and Consumer Health offset flat performance in Pharmaceuticals and significant…
tigation-related cash outflows. Chief Executive Officer Bill Anderson said Bayer posted group sales of about EUR 13.4 billion, up 4% on a currency- and portfolio-adjusted basis
Core earnings per share were EUR 2.71, also higher than the prior-year period. Free cash flow was negative EUR 2.3 billion, which Anderson said was consistent with the company’s outlook because “a significant portion” of litigation-related payments fell in the first quarter. Chief Financial Officer Wolfgang Nickl, who said this was his final quarterly results presentation before handing over the role to Judith in June, said EBITDA before special items reached EUR 4.5 billion, up 9%, or about EUR 370 million, from the prior-year quarter.
He said the increase was led by Crop Science. Crop Science Leads Growth, Supported by Licensing Revenue Anderson said Crop Science sales grew nearly 7% year over year, helped by roughly EUR 450 million in additional soy licensing resolution revenue that Bayer had previously communicated. Excluding that impact, he said the core business grew 1.4%, with strong corn growth offsetting expected declines in crop protection.